EO-3021 is a monoclonal antibody conjugated commercialized by Elevation Oncology, with a leading Phase I program in Solid Tumor. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of EO-3021’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for EO-3021 is expected to reach an annual total of $40 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EO-3021 Overview
SYSA-1801 is under development for the treatment of metastatic gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung cancer, esophageal cancer and pancreatic cancer. The drug candidate comprises of fully human anti-claudin-18.2 monoclonal antibody conjugated with monomethyl auristatin E (MMAE). It is administered through intravenous drip route.
Elevation Oncology Overview
Elevation Oncology is a clinical-stage biopharmaceutical company that discovers and develops therapies to treat cancer. The company’s lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2 for treating metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, and esophageal cancers. Its pipeline also includes ADC to target HER3-expressing cancer; and Seribantumab, an anti-HER3 monoclonal antibody for treatment of solid tumours. The company has worldwide rights outside China to develop and commercialize its products. Elevation Oncology is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$45.5 million in FY2023, compared to an operating loss of US$94.6 million in FY2022. The net loss of the company was US$45.7 million in FY2023, compared to a net loss of US$95.1 million in FY2022.
For a complete picture of EO-3021’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.